​

KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

KALV Stock Forecast

KalVista Pharmaceuticals (KALV) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $22.67, with a high of $28.00 and a low of $20.00. This represents a 73.19% increase from the last price of $13.09.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $22.67 Low: $20 Last Closed Price: $13.09

KALV Stock Rating

KalVista Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

KALV Price Target Upside V Benchmarks

TypeNameUpside
StockKalVista Pharmaceuticals73.19%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$22.67
Last Closing Price$13.09$13.09$13.09
Upside/Downside--73.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2537---10
May, 2537---10
Apr, 2537---10
Mar, 2537---10
Feb, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Serge BelangerNeedham$28.00$11.25148.89%113.90%
Sep 06, 2024Andrew FeinH.C. Wainwright$20.00$12.8755.40%52.79%
Sep 06, 2024Joseph SchwartzLeerink Partners$20.00$12.8755.40%52.79%
Jul 08, 2022Needham$38.00$10.98246.08%190.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 06, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024Leerink PartnersOutperformOutperformhold
Feb 03, 2023SVB LeerinkOutperformOutperformhold
Jul 08, 2022SVB LeerinkOutperformOutperformhold
Jul 08, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 $5 Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported------
Avg Forecast$-3.03$-3.63$-2.76$-1.06$0.68$2.39
High Forecast$-2.85$-3.46$-1.74$-0.02$1.14$4.03
Low Forecast$-3.23$-3.83$-3.56$-2.20$0.38$1.33
Surprise %------

Revenue Forecast

$0 $120M $240M $360M $480M $600M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported------
Avg Forecast$4.46M$5.92M$42.74M$149.88M$271.40M$384.00M
High Forecast$6.81M$9.04M$58.41M$149.88M$414.34M$586.24M
Low Forecast$2.94M$3.91M$35.87M$149.88M$179.15M$253.47M
Surprise %------

Net Income Forecast

$-150M $-90M $-30M $30M $90M $150M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported------
Avg Forecast$-111.87M$-134.12M$-97.52M$-58.31M$24.92M$87.92M
High Forecast$-104.85M$-127.38M$-63.97M$-735.73K$41.99M$148.12M
Low Forecast$-118.88M$-140.86M$-131.08M$-80.93M$13.91M$49.07M
Surprise %------

KALV Forecast FAQ

Is KalVista Pharmaceuticals stock a buy?

KalVista Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that KalVista Pharmaceuticals is a favorable investment for most analysts.

What is KalVista Pharmaceuticals's price target?

KalVista Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $22.67 over the next 12 months. The price target range spans from $20 at the low end to $28 at the high end, suggesting a potential 73.19% change from the previous closing price of $13.09.

How does KalVista Pharmaceuticals stock forecast compare to its benchmarks?

KalVista Pharmaceuticals's stock forecast shows a 73.19% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for KalVista Pharmaceuticals over the past three months?

  • June 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is KalVista Pharmaceuticals’s EPS forecast?

KalVista Pharmaceuticals's average annual EPS forecast for its fiscal year ending in April 2025 is $-3.63, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-2.76 in 2026, $-1.06 in 2027, $0.68 in 2028, and $2.39 in 2029.

What is KalVista Pharmaceuticals’s revenue forecast?

KalVista Pharmaceuticals's average annual revenue forecast for its fiscal year ending in April 2025 is $5.92M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $42.74M, followed by $149.88M for 2027, $271.4M for 2028, and $384M for 2029.

What is KalVista Pharmaceuticals’s net income forecast?

KalVista Pharmaceuticals's net income forecast for the fiscal year ending in April 2025 stands at $-134M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-97.522M in 2026, $-58.309M in 2027, $24.92M in 2028, and $87.92M in 2029.